UMIT - The Health and Life Sciences University, Hall, Tyrol, Austria.
J Thromb Haemost. 2018 Mar;16(3):455-457. doi: 10.1111/jth.13950. Epub 2018 Feb 19.
Recently, two meta-analyses examined the effect of antithrombin on mortality in patients with sepsis and disseminated intravascular coagulation (DIC) with diverging results. In the meta-analysis observing no significant survival effect of antithrombin, the results of a large trial were included under the assumption that all 2314 participants of the trial had sepsis and DIC, which according to post hoc analyses was not the case. To the other meta-analysis reporting beneficial effect, the same trial contributed only those 229 patients that had confirmed sepsis-induced DIC. Replacing the mixed sepsis patient group with and without DIC with the group of sepsis patients with confirmed DIC provides evidence for a beneficial intervention effect of antithrombin also in the meta-analysis that reported no beneficial effect of antithrombin on mortality. This revised result does not change the overall conclusion that the quantity and quality of evidence supporting the use of antithrombin in sepsis patients with DIC is low.
最近,两项荟萃分析研究了抗凝血酶在脓毒症和弥漫性血管内凝血(DIC)患者中的死亡率的影响,结果存在差异。在观察抗凝血酶对死亡率无显著影响的荟萃分析中,纳入了一项大型试验的结果,假设该试验的 2314 名参与者均患有脓毒症和 DIC,但根据事后分析并非如此。而另一份报告抗凝血酶有益效果的荟萃分析中,该试验仅纳入了 229 名确诊脓毒症诱导性 DIC 的患者。用确诊脓毒症合并 DIC 的患者替代合并或不合并 DIC 的混合脓毒症患者,为报告抗凝血酶对死亡率无有益影响的荟萃分析提供了抗凝血酶干预有益的证据。这一修正结果并未改变总体结论,即支持在伴有 DIC 的脓毒症患者中使用抗凝血酶的证据数量和质量均较低。